John. C. Hardman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
John. C. Hardman has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Matthew Edward Smith
University of Cambridge, Cambridge, United Kingdom
10 shared publications - Vinidh Paleri
The Royal Marsden NHS Foundation Trust, London, United Kingdom
10 shared publications - Kristijonas Milinis
Department of Otorhinolaryngology – Head and Neck Surgery Liverpool University Hospitals NHS Foundation Trust Liverpool UK
6 shared publications - Paul Nankivell
Department of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
6 shared publications - Andrew Williamson
International Centre for Recurrent Head and Neck Cancer (IReC), Department of Head and Neck Surgery, The Royal Marsden Hospital, London, UK
4 shared publications INTEGRATE (The UK ENT Trainee Research Network)
4 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Wiley in Head & Neck
Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Glossotonsillar Sulcus Involvement Conveys an Unfavorable Oncological Outcome
Background: Transoral robotic surgery (TORS) is widely used in management of early‐stage primary oropharyngeal squamous cell carcinoma (OPSCC). Tumors involving the glossotonsillar sulcus (GTS) are hypothesized to confer worse oncological outcomes compared to those situated in the rest of the oropharynx, with a paucity of evidence to support this theory. Methods: An observational cohort study of consecutive adult patients undergoing TORS for pT1‐2 oropharyngeal cancers identified over an eight‐year period was conducted. Patients were stratified by oropharyngeal subsite with data collected on patient and tumor characteristics, including histopathological features, and subjected to survival analysis. Results: A total of 153 patients were included, with 52 having tumors involving the GTS. Those with GTS‐involving tumors showed a significantly worse overall survival than patients without. GTS‐involving cancers exhibited a lower proportion of clear margins, and a higher incidence of perineural involvement. Conclusions: GTS involvement conveys a worse prognosis for oropharyngeal cancer patients treated with TORS.
- 19 August 2026
- Published by Wiley in Head & Neck
Open AccessTransoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Glossotonsillar Sulcus Involvement Conveys an Unfavorable Oncological Outcome
Background: Transoral robotic surgery (TORS) is widely used in management of early‐stage primary oropharyngeal squamous cell carcinoma (OPSCC). Tumors involving the glossotonsillar sulcus (GTS) are hypothesized to confer worse oncological outcomes compared to those situated in the rest of the oropharynx, with a paucity of evidence to support this theory. Methods: An observational cohort study of consecutive adult patients undergoing TORS for pT1‐2 oropharyngeal cancers identified over an eight‐year period was conducted. Patients were stratified by oropharyngeal subsite with data collected on patient and tumor characteristics, including histopathological features, and subjected to survival analysis. Results: A total of 153 patients were included, with 52 having tumors involving the GTS. Those with GTS‐involving tumors showed a significantly worse overall survival than patients without. GTS‐involving cancers exhibited a lower proportion of clear margins, and a higher incidence of perineural involvement. Conclusions: GTS involvement conveys a worse prognosis for oropharyngeal cancer patients treated with TORS.
- Open Access
Qualitative study to inform the design and contents of a patient-reported symptom-based risk stratification system for patients referred from primary care on a suspected head and neck cancer diagnostic pathway
Objectives This study aims to inform the development of a patient-reported symptom questionnaire for head and neck cancer and outline the requirements for a patient-reported symptom-based risk stratification system. The study objectives are to explore how clinicians ask questions and decide subsequent steps for patients referred with suspected head and neck cancer; the language patients and clinicians use to describe symptoms; how clinicians reassure and discharge low-risk patients; and identify clinician and patient experiences of the head and neck cancer diagnostic pathway and their views on a novel diagnostic pathway using patient-reported symptom-based risk stratification. Design The study employed qualitative methods including observation and recordings of clinic consultations and semistructured interviews with clinicians and patients. Analysis proceeded concurrently with data collection using a rapid qualitative analysis approach. Setting Three acute UK National Health Service Trusts with variation in service delivery models. Data collection took place between April and October 2023. Participants One hundred and fifty-six adults referred for suspected head and neck cancer, and 21 clinicians from different subspecialties were recruited. A subset of recruited patients (n=16) and clinicians (n=13) were interviewed. One observation of a general head and neck clinic was conducted. Results The findings highlight types of symptoms and the language used by patients and clinicians to describe these symptoms in clinic consultations. During interviews, patients described the need for in-person support and human clinical decision-making, an accessible system for reporting their symptoms and reassurance regarding the security of patient data. Clinicians discussed the need for risk scores to be sufficiently validated to be trusted, the potential clinical usefulness of a risk score-based system, for example, to support triage by discriminating symptoms, and accessibility for patients. The observation highlighted inconsistent and sometimes unclear referral information and the limited time clinicians have to read referral information. Conclusion The findings have implications for the development of a patient-reported symptom-based risk stratification system. As well as ensuring patients can understand the language used, it will be important to consider how their emotional needs can be met. The findings also have wider implications for understanding the impact of language on emotionally evocative healthcare interactions.
Open AccessQualitative study to inform the design and contents of a patient-reported symptom-based risk stratification system for patients referred from primary care on a suspected head and neck cancer diagnostic pathway
Objectives This study aims to inform the development of a patient-reported symptom questionnaire for head and neck cancer and outline the requirements for a patient-reported symptom-based risk stratification system. The study objectives are to explore how clinicians ask questions and decide subsequent steps for patients referred with suspected head and neck cancer; the language patients and clinicians use to describe symptoms; how clinicians reassure and discharge low-risk patients; and identify clinician and patient experiences of the head and neck cancer diagnostic pathway and their views on a novel diagnostic pathway using patient-reported symptom-based risk stratification. Design The study employed qualitative methods including observation and recordings of clinic consultations and semistructured interviews with clinicians and patients. Analysis proceeded concurrently with data collection using a rapid qualitative analysis approach. Setting Three acute UK National Health Service Trusts with variation in service delivery models. Data collection took place between April and October 2023. Participants One hundred and fifty-six adults referred for suspected head and neck cancer, and 21 clinicians from different subspecialties were recruited. A subset of recruited patients (n=16) and clinicians (n=13) were interviewed. One observation of a general head and neck clinic was conducted. Results The findings highlight types of symptoms and the language used by patients and clinicians to describe these symptoms in clinic consultations. During interviews, patients described the need for in-person support and human clinical decision-making, an accessible system for reporting their symptoms and reassurance regarding the security of patient data. Clinicians discussed the need for risk scores to be sufficiently validated to be trusted, the potential clinical usefulness of a risk score-based system, for example, to support triage by discriminating symptoms, and accessibility for patients. The observation highlighted inconsistent and sometimes unclear referral information and the limited time clinicians have to read referral information. Conclusion The findings have implications for the development of a patient-reported symptom-based risk stratification system. As well as ensuring patients can understand the language used, it will be important to consider how their emotional needs can be met. The findings also have wider implications for understanding the impact of language on emotionally evocative healthcare interactions.
- 19 March 2025
- Published by Elsevier in Clinical Oncology
- Vol. 41, 103806
Known Unknowns: Making Sense of Head and Neck Squamous Cell Carcinoma of Unknown Primary
- 19 March 2025
- Published by Elsevier in Clinical Oncology
- Vol. 41, 103806
Known Unknowns: Making Sense of Head and Neck Squamous Cell Carcinoma of Unknown Primary
- 8 January 2025
- Published by Wiley in Clinical Otolaryngology
- Vol. 50 (3) , 462-473
Investigations for Suspected Head and Neck Squamous Cell Carcinoma of Unknown Primary (HNSCCUP): A National Cohort Study
Objectives: Head and neck squamous cell carcinoma from unknown primary (HNSCCUP) is a rare and challenging condition. This study aimed to investigate the diagnostic pathways of suspected HNSCCUP patients in the United Kingdom.Methods: A retrospective observational cohort study was conducted, over 5 years from January 2015, in UK Head and Neck centres of consecutive adults undergoing 18F‐Fluorodeoxyglucose‐PET‐CT (PET‐CT) within 3 months of diagnosis with metastatic cervical squamous cell carcinoma. Patients with no primary site on examination and no previous head and neck cancer were eligible.Results: Data for 965 patients were received from 57 centres; 68.5% were HPV‐related disease. Three investigation cycles were observed: ultrasound with biopsy, cross‐sectional imaging (MRI and/or CT) and PET‐CT, at median times of 17, 29.5 and 46 days from referral. No primary was identified on PET‐CT in 49.8% (n = 478/960). Diagnostic tonsillectomy was performed in 58.2% (n = 278/478) and tongue base mucosectomy (TBM) in 21.7% (n = 104/479). Ipsilateral tonsillectomy carried the highest diagnostic yield (18.7%, n = 52/278), followed by TBM (15.4%, n = 16/104). Contralateral tonsillectomy, performed in 49.0% (n = 234/478), carried the lowest yield (0.9%, n = 2/234). PET‐CT with concurrent MRI was associated with higher primary site detection than PET‐CT with concurrent CT (p = 0.003). A minority of patients undergoing treatment with curative intent received first‐definitive‐treatment within 62 days of referral (15.2%, n = 77/505, median 92 days, IQR: 71–117).Conclusions: Most patients experienced a protracted diagnostic pathway and waited over 3 months for definitive treatment. Earlier PET‐CT with concurrent MRI may expedite diagnosis. TBM appears more productive than contralateral tonsillectomy for primary site detection.
- 8 January 2025
- Published by Wiley in Clinical Otolaryngology
- Vol. 50 (3) , 462-473
Investigations for Suspected Head and Neck Squamous Cell Carcinoma of Unknown Primary (HNSCCUP): A National Cohort Study
Objectives: Head and neck squamous cell carcinoma from unknown primary (HNSCCUP) is a rare and challenging condition. This study aimed to investigate the diagnostic pathways of suspected HNSCCUP patients in the United Kingdom.Methods: A retrospective observational cohort study was conducted, over 5 years from January 2015, in UK Head and Neck centres of consecutive adults undergoing 18F‐Fluorodeoxyglucose‐PET‐CT (PET‐CT) within 3 months of diagnosis with metastatic cervical squamous cell carcinoma. Patients with no primary site on examination and no previous head and neck cancer were eligible.Results: Data for 965 patients were received from 57 centres; 68.5% were HPV‐related disease. Three investigation cycles were observed: ultrasound with biopsy, cross‐sectional imaging (MRI and/or CT) and PET‐CT, at median times of 17, 29.5 and 46 days from referral. No primary was identified on PET‐CT in 49.8% (n = 478/960). Diagnostic tonsillectomy was performed in 58.2% (n = 278/478) and tongue base mucosectomy (TBM) in 21.7% (n = 104/479). Ipsilateral tonsillectomy carried the highest diagnostic yield (18.7%, n = 52/278), followed by TBM (15.4%, n = 16/104). Contralateral tonsillectomy, performed in 49.0% (n = 234/478), carried the lowest yield (0.9%, n = 2/234). PET‐CT with concurrent MRI was associated with higher primary site detection than PET‐CT with concurrent CT (p = 0.003). A minority of patients undergoing treatment with curative intent received first‐definitive‐treatment within 62 days of referral (15.2%, n = 77/505, median 92 days, IQR: 71–117).Conclusions: Most patients experienced a protracted diagnostic pathway and waited over 3 months for definitive treatment. Earlier PET‐CT with concurrent MRI may expedite diagnosis. TBM appears more productive than contralateral tonsillectomy for primary site detection.
- Open Access
- 11 December 2024
- Published by Wiley in International Journal of Language & Communication Disorders
- Vol. 60 (1) , e13137
Speech and language therapist‐led clinics for low‐risk suspected head and neck cancer referrals: A qualitative study of ear, nose and throat surgeons’ views
Background: Over 200,000 patients are referred onto the suspected head and neck cancer (HNC) pathway annually in the UK, with around 3% receiving a cancer diagnosis. With new HNC advancements in identifying patients at low risk of a cancer diagnosis, one proposal is a speech and language therapy (SLT)‐led first point of contact clinic for low‐risk patients presenting with voice or swallowing symptoms.Aims: To explore ear, nose and throat (ENT) surgeons’ views regarding this model.Materials & Methods: The study used a qualitative study design using semi‐structured interviews. Transcribed responses were analysed using thematic analysis.Outcomes & Results: A total of 11 UK ENT surgeons participated. Themes included the positives and challenges of the proposed model; existing facilitators that increase the likelihood of success; and the requirements for successful implementation. Service variation impacted level of interest. Waiting times were problematic at some sites more than others; SLT workforce issues were of differing prevalence; SLT competence and interest differed; and support from organizational leaders varied. Participants’ personal views also varied, for example, acceptability of the model to patients, or what governance structure is required. There was no single SLT‐led clinic model suitable for all centres; however, some general principles were identified to inform further evaluation and implementation of this model.Conclusions & Implications: Principles included the deployment of SLTs experienced in laryngeal examination and flexible nasendoscopy; dedicated job plans and workforce; professional and regulatory body recognition and support; and clear training, supervision structure and job description for the role. Service outcomes, training protocol and competencies require robust evaluation.WHAT THIS PAPER ADDS: What is already known on this subject: During the SARS‐CoV‐2 pandemic, a risk calculator tool was developed to identify patients at highest risk of cancer who were referred to the 2‐week‐wait (2ww) ENT pathway. These patients require urgent face to face ENT assessment. Lower risk patients with voice and swallowing difficulties still require management of their symptoms and an SLT‐led clinic model is one potential solution for this population. While SLTs’ views of this model have been explored with a UK‐wide survey and focus groups, ENT surgeons’ perspectives are yet to be investigated. What this study adds to the existing knowledge: This study explores ENT surgeons’ views regarding SLT‐led clinics for patients who are referred through the 2ww ENT pathway, stratified as being at low risk of cancer, and with voice and/or swallowing symptoms of likely benign aetiology. Participants shared many positive perceptions of the clinic along with factors that they felt would enhance its success (facilitators). Key requirements for the success of this clinic model were also highlighted, along with challenges that need to be addressed. What are the practical and clinical implications of this work?: The need for this clinic model varied by centre. However, general principles included the importance of a dedicated workforce with pre‐existing relevant expertise; and a clear role profile, training process and competencies framework. Professional, statutory and regulatory bodies’ recognition of the role is required, and robust evaluation of the model is necessary.
- 11 December 2024
- Published by Wiley in International Journal of Language & Communication Disorders
- Vol. 60 (1) , e13137
Open AccessSpeech and language therapist‐led clinics for low‐risk suspected head and neck cancer referrals: A qualitative study of ear, nose and throat surgeons’ views
Background: Over 200,000 patients are referred onto the suspected head and neck cancer (HNC) pathway annually in the UK, with around 3% receiving a cancer diagnosis. With new HNC advancements in identifying patients at low risk of a cancer diagnosis, one proposal is a speech and language therapy (SLT)‐led first point of contact clinic for low‐risk patients presenting with voice or swallowing symptoms.Aims: To explore ear, nose and throat (ENT) surgeons’ views regarding this model.Materials & Methods: The study used a qualitative study design using semi‐structured interviews. Transcribed responses were analysed using thematic analysis.Outcomes & Results: A total of 11 UK ENT surgeons participated. Themes included the positives and challenges of the proposed model; existing facilitators that increase the likelihood of success; and the requirements for successful implementation. Service variation impacted level of interest. Waiting times were problematic at some sites more than others; SLT workforce issues were of differing prevalence; SLT competence and interest differed; and support from organizational leaders varied. Participants’ personal views also varied, for example, acceptability of the model to patients, or what governance structure is required. There was no single SLT‐led clinic model suitable for all centres; however, some general principles were identified to inform further evaluation and implementation of this model.Conclusions & Implications: Principles included the deployment of SLTs experienced in laryngeal examination and flexible nasendoscopy; dedicated job plans and workforce; professional and regulatory body recognition and support; and clear training, supervision structure and job description for the role. Service outcomes, training protocol and competencies require robust evaluation.WHAT THIS PAPER ADDS: What is already known on this subject: During the SARS‐CoV‐2 pandemic, a risk calculator tool was developed to identify patients at highest risk of cancer who were referred to the 2‐week‐wait (2ww) ENT pathway. These patients require urgent face to face ENT assessment. Lower risk patients with voice and swallowing difficulties still require management of their symptoms and an SLT‐led clinic model is one potential solution for this population. While SLTs’ views of this model have been explored with a UK‐wide survey and focus groups, ENT surgeons’ perspectives are yet to be investigated. What this study adds to the existing knowledge: This study explores ENT surgeons’ views regarding SLT‐led clinics for patients who are referred through the 2ww ENT pathway, stratified as being at low risk of cancer, and with voice and/or swallowing symptoms of likely benign aetiology. Participants shared many positive perceptions of the clinic along with factors that they felt would enhance its success (facilitators). Key requirements for the success of this clinic model were also highlighted, along with challenges that need to be addressed. What are the practical and clinical implications of this work?: The need for this clinic model varied by centre. However, general principles included the importance of a dedicated workforce with pre‐existing relevant expertise; and a clear role profile, training process and competencies framework. Professional, statutory and regulatory bodies’ recognition of the role is required, and robust evaluation of the model is necessary.
- Open Access
- 30 July 2024
- Published by Wiley in Clinical Otolaryngology
- Vol. 49 (6) , 837-841
Management of Head Neck Squamous Cell Cancer From an Unknown Primary: Systematic Reviews and National Audit Outcome Data to Generate National Guidelines
- 30 July 2024
- Published by Wiley in Clinical Otolaryngology
- Vol. 49 (6) , 837-841
Open AccessManagement of Head Neck Squamous Cell Cancer From an Unknown Primary: Systematic Reviews and National Audit Outcome Data to Generate National Guidelines
- Open Access
Management of head neck squamous cell cancer from an unknown primary: systematic reviews and national audit outcome data to generate national guidelines
We take great pleasure in introducing this supplement dedicated to management of head neck squamous cell cancer from an unknown primary (HSCCUP).
Open AccessManagement of head neck squamous cell cancer from an unknown primary: systematic reviews and national audit outcome data to generate national guidelines
We take great pleasure in introducing this supplement dedicated to management of head neck squamous cell cancer from an unknown primary (HSCCUP).
- Open Access
- 14 July 2024
- Published by Elsevier in Oral Oncology Reports
- Vol. 11
Incidental dose to the oropharynx with involved neck only radiotherapy in squamous cell cancer of unknown primary of the head and neck
- 14 July 2024
- Published by Elsevier in Oral Oncology Reports
- Vol. 11
Open AccessIncidental dose to the oropharynx with involved neck only radiotherapy in squamous cell cancer of unknown primary of the head and neck
- 20 May 2024
- Published by Wiley in Clinical Otolaryngology
- Vol. 49 (5) , 604-620
Survival outcomes in head and neck squamous cell carcinoma of unknown primary: A national cohort study
Introduction: To investigate factors influencing survival in head and neck squamous cell carcinoma of unknown primary (HNSCCUP).Methods: A retrospective observational cohort study was conducted, over 5 years from January 2015, in UK Head and Neck centres, of consecutive adults undergoing 18F‐Fluorodeoxyglucose‐PET‐CT within 3 months of diagnosis with metastatic cervical squamous cell carcinoma. Patients treated as HNSCCUP underwent survival analysis, stratified by neck dissection and/or radiotherapy to the ipsilateral neck, and by HPV status.Results: Data were received from 57 centres for 965 patients, of whom 482 started treatment for HNSCCUP (65.7% HPV‐positive, n = 282/429). Five‐year overall survival (OS) for HPV‐positive patients was 85.0% (95% CI 78.4–92.3) and 43.5% (95% CI 32.9–57.5) for HPV‐negative. HPV‐negative status was associated with worse OS, disease‐free (DFS), and disease‐specific (DSS) survival (all p < .0001 on log‐rank test) but not local control (LC) (p = .16). Unilateral HPV‐positive disease treated with surgery alone was associated with significantly worse DFS (p < .0001) and LC (p < .0001) compared to radiotherapy alone or combined modalities (5‐year DFS: 24.9%, 82.3% and 94.3%; 5‐year LC: 41.8%, 98.8% and 98.6%). OS was not significantly different (p = .16). Unilateral HPV‐negative disease treated with surgery alone was associated with significantly worse LC (p = .017) (5‐year LC: estimate unavailable, 93.3% and 96.6%, respectively). Small numbers with bilateral disease precluded meaningful sub‐group analysis.Conclusions: HPV status is associated with variable management and outcomes in HNSCCUP. Unilateral neck disease is treated variably and associated with poorer outcomes when managed with surgery alone. The impact of diagnostic oropharyngeal surgery on primary site emergence, survival and functional outcomes is unestablished.
- 20 May 2024
- Published by Wiley in Clinical Otolaryngology
- Vol. 49 (5) , 604-620
Survival outcomes in head and neck squamous cell carcinoma of unknown primary: A national cohort study
Introduction: To investigate factors influencing survival in head and neck squamous cell carcinoma of unknown primary (HNSCCUP).Methods: A retrospective observational cohort study was conducted, over 5 years from January 2015, in UK Head and Neck centres, of consecutive adults undergoing 18F‐Fluorodeoxyglucose‐PET‐CT within 3 months of diagnosis with metastatic cervical squamous cell carcinoma. Patients treated as HNSCCUP underwent survival analysis, stratified by neck dissection and/or radiotherapy to the ipsilateral neck, and by HPV status.Results: Data were received from 57 centres for 965 patients, of whom 482 started treatment for HNSCCUP (65.7% HPV‐positive, n = 282/429). Five‐year overall survival (OS) for HPV‐positive patients was 85.0% (95% CI 78.4–92.3) and 43.5% (95% CI 32.9–57.5) for HPV‐negative. HPV‐negative status was associated with worse OS, disease‐free (DFS), and disease‐specific (DSS) survival (all p < .0001 on log‐rank test) but not local control (LC) (p = .16). Unilateral HPV‐positive disease treated with surgery alone was associated with significantly worse DFS (p < .0001) and LC (p < .0001) compared to radiotherapy alone or combined modalities (5‐year DFS: 24.9%, 82.3% and 94.3%; 5‐year LC: 41.8%, 98.8% and 98.6%). OS was not significantly different (p = .16). Unilateral HPV‐negative disease treated with surgery alone was associated with significantly worse LC (p = .017) (5‐year LC: estimate unavailable, 93.3% and 96.6%, respectively). Small numbers with bilateral disease precluded meaningful sub‐group analysis.Conclusions: HPV status is associated with variable management and outcomes in HNSCCUP. Unilateral neck disease is treated variably and associated with poorer outcomes when managed with surgery alone. The impact of diagnostic oropharyngeal surgery on primary site emergence, survival and functional outcomes is unestablished.
- Open Access
Qualitative study exploring the design of a patient-reported symptom-based risk stratification system for suspected head and neck cancer referrals: protocol for work packages 1 and 2 within the EVEREST-HN programme
Introduction Between 2009/2010 and 2019/2020, England witnessed an increase in suspected head and neck cancer (sHNC) referrals from 140 to 404 patients per 100 000 population. 1 in 10 patients are not seen within the 2-week target, contributing to patient anxiety. We will develop a pathway for sHNC referrals, based on the Head and Neck Cancer Risk Calculator. The evolution of a patient-reported symptom-based risk stratification system to redesign the sHNC referral pathway (EVEREST-HN) Programme comprises six work packages (WPs). This protocol describes WP1 and WP2. WP1 will obtain an understanding of language to optimise the SYmptom iNput Clinical (SYNC) system patient-reported symptom questionnaire for sHNC referrals and outline requirements for the SYNC system. WP2 will codesign key elements of the SYNC system, including the SYNC Questionnaire, and accompanying behaviour change materials. Methods and analysis WP1 will be conducted at three acute National Health Service (NHS) trusts with variation in service delivery models and ensuring a broad mixture of social, economic and cultural backgrounds of participants. Up to 150 patients with sHNC (n=50 per site) and 15 clinicians (n=5 per site) will be recruited. WP1 will use qualitative methods including interviews, observation and recordings of consultations. Rapid qualitative analysis and inductive thematic analysis will be used to analyse the data. WP2 will recruit lay patient representatives to participate in online focus groups (n=8 per focus group), think-aloud technique and experience-based codesign and will be analysed using qualitative and quantitative approaches. Ethics and dissemination The committee for clinical research at The Royal Marsden, a research ethics committee and the Health Research Authority approved this protocol. All participants will give informed consent. Ethical issues of working with patients on an urgent cancer diagnostic pathway have been considered. Findings will be disseminated via journal publications, conference presentations and public engagement activities.
Open AccessQualitative study exploring the design of a patient-reported symptom-based risk stratification system for suspected head and neck cancer referrals: protocol for work packages 1 and 2 within the EVEREST-HN programme
Introduction Between 2009/2010 and 2019/2020, England witnessed an increase in suspected head and neck cancer (sHNC) referrals from 140 to 404 patients per 100 000 population. 1 in 10 patients are not seen within the 2-week target, contributing to patient anxiety. We will develop a pathway for sHNC referrals, based on the Head and Neck Cancer Risk Calculator. The evolution of a patient-reported symptom-based risk stratification system to redesign the sHNC referral pathway (EVEREST-HN) Programme comprises six work packages (WPs). This protocol describes WP1 and WP2. WP1 will obtain an understanding of language to optimise the SYmptom iNput Clinical (SYNC) system patient-reported symptom questionnaire for sHNC referrals and outline requirements for the SYNC system. WP2 will codesign key elements of the SYNC system, including the SYNC Questionnaire, and accompanying behaviour change materials. Methods and analysis WP1 will be conducted at three acute National Health Service (NHS) trusts with variation in service delivery models and ensuring a broad mixture of social, economic and cultural backgrounds of participants. Up to 150 patients with sHNC (n=50 per site) and 15 clinicians (n=5 per site) will be recruited. WP1 will use qualitative methods including interviews, observation and recordings of consultations. Rapid qualitative analysis and inductive thematic analysis will be used to analyse the data. WP2 will recruit lay patient representatives to participate in online focus groups (n=8 per focus group), think-aloud technique and experience-based codesign and will be analysed using qualitative and quantitative approaches. Ethics and dissemination The committee for clinical research at The Royal Marsden, a research ethics committee and the Health Research Authority approved this protocol. All participants will give informed consent. Ethical issues of working with patients on an urgent cancer diagnostic pathway have been considered. Findings will be disseminated via journal publications, conference presentations and public engagement activities.